Brazil Patient Derived Xenografts/PDX Models Market (2025-2030)
The Brazil Patient Derived Xenografts/PDX Models Market was valued at $2.49 Million in 2025 and projected to reach to $3.64 Million by 2030, representing a compound annual growth rate of 7.9%. Brazil's PDX models market is positioned for steady growth as the country strengthens its position in precision oncology research.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Brazil Patient Derived Xenografts/PDX Models Market Trends and Insights
- Brazil is emerging as a key market within Latin America for PDX model adoption, driven by increasing investment in precision medicine and oncology research.
- The market in Brazil reflects growing recognition of PDX models' critical role in drug development and personalized cancer treatment strategies. During the 2025–2030 forecast period, Brazil's PDX market will benefit from enhanced research infrastructure and collaborations between academic institutions and pharmaceutical companies.
- Brazil's healthcare sector is increasingly adopting advanced preclinical models to accelerate drug discovery timelines and improve clinical trial success rates.
- The expansion in Brazil is supported by rising government funding for life sciences research and a growing number of contract research organizations (CROs) specializing in oncology models. Brazil's market growth is tempered by infrastructure limitations and competition from alternative model systems, yet the country's large patient population and expanding biotech ecosystem position it as a strategic hub for PDX development in Latin America.
- Continued investment in research capabilities and regulatory support will be essential to sustaining Brazil's market momentum through 2030..
Key Market Statistics
- CAGR (2025-2030) 7.9% CAGR
- Market Size, 2025 ~USD 2.49 Million
- Forecast, 2030 ~USD 3.64 Million
- Country Brazil
Brazil Patient Derived Xenografts/PDX Models Market Overview
Market Valuation :
Brazil's PDX models market is valued at USD 2.49 million in 2025, with projected growth to USD 3.64 million by 2030, representing a CAGR of 7.9%.
Latin American Leadership :
Brazil is emerging as a key market within Latin America for PDX model adoption, driven by increasing investment in precision medicine and oncology research initiatives.
Growth Drivers :
Rising demand for personalized cancer treatment, expanding pharmaceutical R&D capabilities, and government support for biotechnology innovation are fueling market expansion in Brazil.
Research Infrastructure :
Growing number of research institutions and cancer centers in Brazil are adopting PDX models for drug development and clinical trial optimization.
Brazil Patient Derived Xenografts/PDX Models Market Dynamics
- Increasing collaborations between Brazilian research institutions and international pharmaceutical companies are accelerating PDX model adoption.
- Government initiatives supporting biotechnology development and rising healthcare investments create favorable conditions for market expansion. The market will benefit from growing awareness of personalized medicine benefits among healthcare providers and pharmaceutical companies operating in Brazil.
- Enhanced regulatory frameworks and improved access to advanced research technologies are expected to drive adoption rates.
- By 2030, Brazil is anticipated to become a significant hub for PDX-based drug development in Latin America, attracting both domestic and international investment..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Brazil's PDX models market is valued at USD 2.49 million in 2025 and will reach USD 3.64 million by 2030, representing a 7.9% CAGR.
- Brazil is strengthening its position as a regional leader in precision oncology research through increased academic-industry partnerships and CRO expansion.
- Government funding initiatives and infrastructure development in Brazil are accelerating adoption of PDX models for drug discovery and personalized medicine.
- Brazil's large patient population and growing biotech ecosystem create significant opportunities for PDX model development, though infrastructure challenges remain.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Brazil Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER,2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.66 | 0.71 | 0.77 | 0.83 | 0.89 | 0.96 | 1.03 | 1.1 | 7.5 |
| CROS & CDMOS | 0.43 | 0.47 | 0.5 | 0.54 | 0.58 | 0.62 | 0.66 | 0.71 | 7 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 1.39 | 1.51 | 1.65 | 1.8 | 1.95 | 2.11 | 2.28 | 2.47 | 8.4 |
| TOTAL | 2.48 | 2.69 | 2.92 | 3.17 | 3.43 | 3.69 | 3.97 | 4.27 | 7.9 |
Target Audience
- Pharmaceutical Companies : Seeking to establish PDX research capabilities in Brazil or expand oncology drug development pipelines through partnerships with local research institutions and CROs.
- Biotech and CRO Firms : Evaluating Brazil as a location for PDX model development services, preclinical research, and clinical trial support to serve regional and global pharmaceutical clients.
- Research Institutions : Planning to implement or expand PDX capabilities need market data to justify investments, secure funding, and identify collaboration opportunities with industry partners.
- Investment and Private Equity : Analyzing Brazil's precision medicine and biotech sectors require detailed market intelligence to identify acquisition targets and assess growth potential in PDX-related businesses.
- Healthcare Policy Makers : Developing precision medicine initiatives and biotechnology strategies in Brazil need market insights to inform policy decisions and allocate resources effectively.
Key Companies in the Brazil Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Market Entry Strategy : Comprehensive analysis of Brazil's PDX market dynamics enables pharmaceutical and biotech companies to develop targeted market entry strategies and identify partnership opportunities with local research institutions.
- Competitive Intelligence : Detailed insights into Brazil's market landscape, key players, and growth drivers provide competitive advantage for companies seeking to establish or expand PDX operations in Latin America.
- Investment Decision Support : Accurate market sizing and growth projections for Brazil help investors evaluate opportunities in the precision medicine sector and make informed capital allocation decisions.
- Regulatory and Operational Insights : Understanding Brazil-specific regulatory environment, research infrastructure, and adoption barriers enables companies to optimize operations and accelerate market penetration.
- Growth Opportunity Identification : Detailed forecast data through 2030 identifies emerging segments and geographic opportunities within Brazil's PDX market for product development and service expansion.
Frequently asked questions
What is the current market size of PDX models in Brazil?
Brazil's PDX models market is valued at USD 2.49 million in 2025 and is expected to grow to USD 3.64 million by 2030.
What is the projected growth rate for Brazil's PDX market?
Brazil's PDX models market is projected to grow at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2030.
What factors are driving PDX model adoption in Brazil?
Key drivers include increased government funding for life sciences research, growing academic-industry collaborations, expansion of contract research organizations, and rising demand for precision oncology solutions in Brazil.
What challenges does Brazil's PDX market face?
Brazil's PDX market faces challenges including infrastructure limitations, competition from alternative preclinical models, and the need for continued regulatory support and investment in research capabilities.
How does Brazil's PDX market compare to other Latin American countries?
Brazil is emerging as a key regional hub for PDX model adoption in Latin America, driven by its large patient population, expanding biotech ecosystem, and increasing research infrastructure investments.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report